Correct Administration of Tucatinib

Release date: 2026-05-25 16:15:28     Recommended: 29

Correct Administration of Tucatinib

Tucatinib is an oral tablet taken twice daily, within 30 minutes after a meal. It is used in combination with trastuzumab (usually administered intravenously) and capecitabine (oral). Capecitabine is given in cycles of 14 consecutive days of treatment followed by a 7-day rest period, then the next cycle begins. Note that during the last 7 days of each cycle when capecitabine is withheld, tucatinib should still be taken daily without interruption. Tucatinib and capecitabine can be taken at the same time. Be sure to follow your healthcare provider's instructions exactly, and do not adjust the dose or stop treatment on your own. If certain side effects occur, your doctor may adjust your tucatinib dose, temporarily interrupt treatment, or permanently discontinue it.

Unique Mechanism of Tucatinib Combined with Trastuzumab

HER2-positive cancer cells are characterized by an abundance of HER2 receptor proteins on their surface, which continuously transmit signals promoting cell growth and division. Traditional anti-HER2 therapies such as trastuzumab have a large molecular weight and primarily bind to the HER2 receptor from the outside of the cell, blocking signal transduction. However, external blockade alone sometimes cannot completely inhibit all signaling pathways. Tucatinib is a small-molecule tyrosine kinase inhibitor, with a molecular size much smaller than that of trastuzumab, enabling it to easily penetrate the cell membrane and inhibit HER2 activity from within the cell. When tucatinib is combined with trastuzumab, the two produce a synergistic "inside-and-outside attack": trastuzumab intercepts signals at the cell surface, while tucatinib cuts off the signaling pathway inside the cell. This dual blockade can more comprehensively and thoroughly suppress cancer cell growth signals, thereby delaying disease progression. This is the molecular basis for why the tucatinib regimen achieved superior efficacy compared to trastuzumab alone in clinical studies. Of course, because HER2 is also present on some normal cells, this targeted action may also affect healthy tissues, leading to corresponding side effects.

Tucatinib Brings New Hope for Intracranial Lesions

In patients with HER2-positive metastatic breast cancer, brain metastasis is a common and challenging complication. Traditional large-molecule anti-HER2 drugs (e.g., trastuzumab, pertuzumab) have difficulty effectively crossing the blood-brain barrier due to their large molecular weight, providing limited control of intracranial metastatic lesions. As a small-molecule drug, tucatinib has better blood-brain barrier penetration. The HER2CLIMB study specifically enrolled 291 patients (48% of the total) with brain metastases, including 40% with stable brain metastases and 60% with active brain metastases (i.e., growing or spreading). Results showed that for patients with brain metastases, the median progression-free survival in the group receiving tucatinib plus trastuzumab and capecitabine was 7.6 months, compared to 5.4 months in the control group. Compared with the control group, the tucatinib regimen reduced the risk of disease progression or death by 52% in patients with brain metastases. These breakthrough data indicate that even after cancer has spread to the brain, tucatinib can still exert effective anti-tumor activity, offering a new treatment option for patients with brain metastases, previously considered a forbidden zone.